Immunohistochemistry (IHC) of 107 clinical brain specimens revealed DNAJC10 was largely undetected or reduced in GBM (WHO grade 4) samples, but prevalent in low-grade gliomas (Fig. 1c,d and Table S2). This evidence concerns the gene DNAJC10 and central nervous system cancer.